Loading…
Jaguar Health, Inc. is projected to decline to $0.9843 by 2027, a -2% move from its current price of $1.00. JAGX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.9311 | $1.00 | $1.08 | +0.10% |
| Aug 6 | $0.9045 | $1.00 | $1.11 | +0.20% |
| Aug 7 | $0.8847 | $1.00 | $1.14 | +0.30% |
| Aug 8 | $0.8686 | $1.00 | $1.16 | +0.40% |
| Aug 9 | $0.8547 | $1.00 | $1.18 | +0.50% |
| Aug 10 | $0.8425 | $1.01 | $1.20 | +0.60% |
| Aug 11 | $0.8314 | $1.01 | $1.22 | +0.70% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8314 | $1.01 | $1.22 | +0.70% |
| Week 2 | $0.7733 | $1.01 | $1.33 | +1.40% |
| Week 3 | $0.7327 | $1.02 | $1.42 | +2.10% |
| Week 4 | $0.7009 | $1.03 | $1.51 | +2.81% |
| Week 5 | $0.6745 | $1.04 | $1.59 | +3.53% |
| Week 6 | $0.652 | $1.04 | $1.67 | +4.25% |
| Week 7 | $0.6323 | $1.05 | $1.74 | +4.97% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health, and concentrates on developing and commercializing prescription and non-prescription products for companion and production animals, and human products.
Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients, and NP-300, a second-generation antidiarrheal drug in Phase I. The company is headquartered in San Francisco, California.
Jaguar Health, Inc. trades as JAGX and has a current price of $1.03 with a market cap of $5.06M, ranking 5186. The company operates in Healthcare as a specialist in plant-based medicines for GI distress in humans and animals.
The near-term price signal is neutral, and long-run forecasts show a wide range of potential outcomes across multiple years, culminating in substantial upside in some later years.
In the multi-year forecast, the average price moves from around $1.03 in 2026 to a higher-range outcome by 2050, with the greatest upside occurring in the 2040–2050 window. The forecast highlights both bear cases in the near term and bullish possibilities later, emphasizing the high uncertainty and variability in this security.
A major floor 3.7% below — a decisive break under it would weaken the trend.
The nearest floor, 3.7% below — buyers have tended to step in here.
The nearest ceiling, 204.0% above — a clean break opens room to run.
A major ceiling 1401.5% above — clearing it would confirm fresh momentum.
Key JAGX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of JAGX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.994 | Buy | $1.02 | Sell |
| MA 10 | $1.08 | Sell | $1.17 | Sell |
| MA 20 | $1.62 | Sell | $1.54 | Sell |
| MA 50 | $2.39 | Sell | $3.25 | Sell |
| MA 100 | $6.83 | Sell | $10.16 | Sell |
| MA 200 | $24.04 | Sell | $333.35 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 23.17 | Buy |
| Stoch RSI (14) | 36.08 | Neutral |
| CCI (20) | -69.06 | Neutral |
| Williams %R (14) | -96.93 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -48.72 | Sell |
| Bollinger %B (20,2) | 0.26 | Neutral |
| Stochastic %K (14) | 3.07 | Buy |
| TRIX (15) | -2.94 | Sell |
| Awesome (5,34) | -1.06 | Sell |
| Ultimate (7,14,28) | 18.20 | Buy |
| Momentum (10) | -0.30 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 0.96 | Buy |
| ADX (14) | 47.73 | Sell |
| ATR (14) | 0.12 | Info |
The 30-day technical picture is neutral with RSI14 at 20. The stock’s price path is reflected by SMA50 of $2.70 and SMA200 of $26.29, indicating a wide gap between short- and long-term averages.
Support is cited at $1.03 and resistance at $3.04. The 30-day trading range runs from a low of $0.5865 to a high of $1.81, and the annualized volatility is 200%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.963 | $1.00 | $1.49 | 0% | Neutral | |
| $0.7173 | $0.9843 | $1.46 | -2% | Neutral | |
| $0.5623 | $0.8207 | $1.30 | -18% | Bearish | |
| $0.545 | $0.8382 | $1.39 | -16% | Bearish | |
| $0.5171 | $0.834 | $1.44 | -17% | Bearish | |
| $0.6149 | $1.04 | $1.86 | +4% | Neutral | |
| $0.6918 | $1.22 | $2.25 | +22% | Bullish | |
| $0.6907 | $1.27 | $2.40 | +27% | Bullish | |
| $0.6797 | $1.30 | $2.52 | +30% | Bullish | |
| $0.569 | $1.13 | $2.25 | +13% | Neutral | |
| $0.7557 | $1.68 | $3.68 | +68% | Bullish | |
| $1.13 | $2.51 | $5.77 | +151% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.963 | $1.00 | $1.24 | +0.00% |
| September 2026 | $0.8887 | $1.08 | $1.37 | +8.02% |
| October 2026 | $0.8881 | $1.09 | $1.42 | +1.33% |
| November 2026 | $0.857 | $1.07 | $1.41 | -2.39% |
| December 2026 | $0.8841 | $1.11 | $1.49 | +4.25% |
Click any year to see its month-by-month JAGX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, JAGX is projected to trade between $0.963 and $1.49, averaging $1.00 — a potential gain of 0% from today's $1.00. A consolidation phase looks the most probable path here.
Jaguar Health, Inc.'s 2027 outlook centres on $0.9843, within a $0.7173 to $1.46 range. That is -2% versus the projected 2026 average. That marks a -2% change versus current levels. Price action looks broadly range-bound.
By 2028, JAGX could reach as high as $1.30, with a base case around $0.8207 and support toward $0.5623 — roughly -18% from $1.00. Expect choppier, lower action through this leg of the cycle.
Expect JAGX to range from $0.545 to $1.39 through 2029. The $0.8382 average target implies a -16% move from current prices. That is up +2% on the projected 2028 average. A cyclical pullback looks likely — prices rarely move in a straight line.
The JAGX price prediction for 2030 points to an average of $0.834 (low $0.5171, high $1.44) — a potential decline of -17% on today's $1.00. Expect choppier, lower action through this leg of the cycle.
In 2031, JAGX is projected to trade between $0.6149 and $1.86, averaging $1.04 — a potential gain of +4% from today's $1.00. That is up +24% on the projected 2030 average. Price action looks broadly range-bound.
Jaguar Health, Inc.'s 2032 outlook centres on $1.22, within a $0.6918 to $2.25 range. That is up +17% on the projected 2031 average. That marks a +22% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, JAGX could reach as high as $2.40, with a base case around $1.27 and support toward $0.6907 — roughly +27% from $1.00. Momentum favours further upside here.
Expect JAGX to range from $0.6797 to $2.52 through 2034. The $1.30 average target implies a +30% move from current prices. That is up +2% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The JAGX price prediction for 2035 points to an average of $1.13 (low $0.569, high $2.25) — a potential gain of +13% on today's $1.00. Price action looks broadly range-bound.
In 2040, JAGX is projected to trade between $0.7557 and $3.68, averaging $1.68 — a potential gain of +68% from today's $1.00. That is up +49% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Jaguar Health, Inc.'s 2050 outlook centres on $2.51, within a $1.13 to $5.77 range. That is up +49% on the projected 2040 average. That marks a +151% change versus current levels. Momentum favours further upside here.
Investing $1,000 in JAGX today (≈ 1,000 JAGX) could be worth
$2,509.94
+$1,509.94 (+151%) by 2050 · US Dollar
Based on the average projected JAGX price of $2.51 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in JAGXwould be worth at today's price.
$1,000 invested in JAGX on Jul 31, 2025 (≈ 14.005602 JAGX) would be worth
$14.01
-$985.99 (-98.6%) today · 0.01× · US Dollar
Based on a JAGX entry price of $71.4 vs. today's $1.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.963 | $1,038.42 | +3.8% |
| 1 month ago | $3.04 | $328.95 | -67.1% |
| 3 months ago | $6.69 | $149.48 | -85.1% |
| 6 months ago | $22.4 | $44.64 | -95.5% |
| 1 year ago | $71.4 | $14.01 | -98.6% |
| All time (5.0y) ago | $15,710,625 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our JAGX forecast.
Our base-case forecast reaches $2.00 around 2050.
Implied market cap at $2.00: $9.82M
The year-by-year forecast shows a mixed path with several notable milestones. The 2026 forecast is $1.03 (min $1.03, max $1.57) with 0% ROI and neutral sentiment. In 2032–2034 the forecast turns bullish, with 2032 avg $1.29, 2033 avg $1.29, and 2034 avg $1.33; ROI in these years runs at 25%, 24.8%, and 29% respectively, with bullish sentiment.
By 2040 the forecast strengthens to an avg of $1.73 with a max of $3.80 and a 68.3% ROI, supported by a bullish sentiment. In 2050 the avg price is $2.64 with a max of $6.08 and a 156.5% ROI, also with bullish sentiment.
Overall, the longer horizon shows meaningful upside potential in certain years, but the path includes years with bear signals (e.g., 2028, 2029, 2030) and notable near-term volatility. These figures are estimates and not guarantees, reflecting a range of possible outcomes rather than a single forecast.
Tap a question to reveal the answer.
2030 forecast: min $0.5246, avg $0.8472, max $1.47; ROI -17.8%; sentiment BEARISH.
The forecast shows mixed signals: near-term years such as 2028 and 2030 are bearish with negative ROIs (e.g., 2028 ROI -19.6%, 2030 ROI -17.8%), while later years such as 2040 (ROI 68.3%, avg $1.73) and 2050 (ROI 156.5%, avg $2.64) are bullish.
The forecast maximums include $3.80 in 2040 and $6.08 in 2050, indicating that higher price levels are possible in the longer term.
30-day range: low $0.5865, high $1.81.
Jaguar Health, Inc. Community Discussion
0Share your Jaguar Health, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.